Application of electronic medical record data for health outcomes research: a review of recent literature.

abstract：:The rapid rise in health care expenses has resulted in an increased interest in the cost of treatments from a cost-effectiveness point of view for management purposes and in a reimbursement setting. The economics of radiotherapy within the global context of health care, and more specifically of cancer therapy, are dis...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lievens Y,Slotman BJ

更新日期：2003-08-01 00:00:00

abstract：INTRODUCTION:Alcohol use is a major risk factor for mortality and morbidity burden, and alcohol use disorders contribute markedly to this burden. Effective interventions for alcohol use disorders improve health, and are potentially cost-effective or even cost saving. AREAS COVERED:We searched the literature for the co...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Rehm J,Barbosa C

更新日期：2018-02-01 00:00:00

abstract：:Osteoarthritis is the single most important cause of disability and limitation of activity of elderly people in the UK. Although joint replacement is now commonplace for hips and increasingly so for knees, pharmacological management continues to be important. In this context, it is necessary to identify valid and acce...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Walters SJ,Lloyd-Jones M

更新日期：2002-08-01 00:00:00

abstract：:Quality of life has become an important end point in clinical trials and academic studies. The questionnaires developed by the European Organisation for Research and Treatment of Cancer Quality of Life Group are widely used to measure quality of life in cancer patients. The expanding geographical coverage of current s...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kuliś D,Arnott M,Greimel ER,Bottomley A,Koller M,European Organisation for Research and Treatment of Cancer Quality of Life Group.

更新日期：2011-06-01 00:00:00

abstract：:Quality-adjusted life-years (QALYs) play an important role in reimbursement decisions when one of the criteria is the cost-effectiveness of the health technology. While for many generic QALYs (e.g., based on the EQ-5D) are viewed as the gold standard, there has been a considerable increase in interest in using conditi...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Petrillo J,Cairns J

更新日期：2008-10-01 00:00:00

abstract：:Given growing interest in multicriteria decision making and multiple cost-effectiveness thresholds' approach, it was decided to investigate its usefulness in Poland. The pricing and reimbursement (P&R) regulations were reviewed and a cross-sectional survey was conducted amongst nurses. The study investigated whether P...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kolasa K

更新日期：2014-10-01 00:00:00

abstract：:Differential item functioning (DIF) analyses are used to determine whether certain groups respond differently to a particular item of a test or questionnaire; however, these do not explain the reasons for observed response differences. Many studies have used external reviews of items, sometimes using blinded reviewers...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Scott NW,Fayers PM,Aaronson NK,Bottomley A,de Graeff A,Groenvold M,Gundy C,Koller M,Petersen MA,Sprangers MA,EORTC Quality of Life Group.,Quality of Life Cross-Cultural Meta-Analysis Group.

更新日期：2010-06-01 00:00:00

abstract：:Despite the intense debates over state or private sector dominance in healthcare finance and provision, there are no clear winners. Failed models exist on either end of the ideological spectrum and no country in the world has one that is purely public or purely private. Neither does a perfect public-private mix exist;...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Lim MK

更新日期：2006-12-01 00:00:00

abstract：:Rates of antibiotic resistance in Pseudomonas aeruginosa are increasing worldwide. The multidrug-resistant (MDR) phenotype in P. aeruginosa could be mediated by several mechanisms including multidrug efflux systems, enzyme production, outer membrane protein (porin) loss and target mutations. Currently, no internationa...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hirsch EB,Tam VH

更新日期：2010-08-01 00:00:00

abstract：:Chronic obstructive pulmonary disease is a major cause of morbidity and mortality throughout the world. Standard management includes avoidance of causative factors such as smoking, and pharmacological therapy with combinations of inhaled and/or oral bronchodilators and corticosteroids. Lung transplantation is an estab...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Reed A,Williams T,Snell G

更新日期：2003-12-01 00:00:00

abstract：:Parkinson's disease (PD) is the second most common neurological disease affecting older adults. Consequently, this disease should be a focus among payers, with increasing utilization of newer premium-priced patent-protected add-on therapies to stabilize or even improve motor function over time. However, expenditure ca...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Brkicic LS,Godman B,Voncina L,Sovic S,Relja M

更新日期：2012-06-01 00:00:00

abstract：:Nursing homes are facing increased environmental pressures to improve quality of care. However, this increased emphasis on quality comes at a time when nursing homes are facing revenue constraints as a result of the repeal of the Boren amendment, increased reimbursement based on prospective payment systems and widespr...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Weech-Maldonado R,Mor V,Oluwole A

更新日期：2004-02-01 00:00:00

abstract：:A systematic review was conducted of the full economic evaluations of the cost-effectiveness of peginterferon alfa-2b (PEG-IFN alfa-2b) plus ribavirin (RBV) in the treatment of chronic hepatitis C (CHC). A total of 439 references were screened and 11 studies were included. The studies employed decision analytic Markov...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Shepherd J,Jones J

更新日期：2007-12-01 00:00:00

abstract：BACKGROUND:Biosimilars can directly reduce the cost of treating patients for whom a reference biologic is indicated by offering a highly similar, lower priced alternative. We examine factors related to biosimilar regulatory approval, uptake, pricing, and financing and the potential impact on drug expenditures in the U....

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Grewal S,Ramsey S,Balu S,Carlson JJ

更新日期：2018-08-01 00:00:00

abstract：:There have been great technological advances in the use of antiretroviral therapies to slow down disease progression in HIV/AIDS. Combinations of therapeutics and the use of several diagnostic methods have resulted in both declines in mortality and the occurrence of opportunistic infections. The higher costs of these ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Bos JM,Berg LT,Postma MJ

更新日期：2001-10-01 00:00:00

abstract：OBJECTIVES:This cross-sectional study examined the prevalence and burden of major depressive disorder (MDD) among adults in urban China. METHODS:Data were included from the 2012 China National Health and Wellness Survey. Respondents self-reporting physician diagnosis of depression and screening positive for MDD (Patie...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gupta S,Goren A,Dong P,Liu D

更新日期：2016-06-01 00:00:00

abstract：:Social Security Disability Insurance provides cash benefits to disabled workers and certain others under the age of 65 years. These individuals become eligible for Medicare 24 months after Social Security Disability Insurance cash benefits start. In 2001, 13.9% of Medicare's approximately 40 million beneficiaries were...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Iezzoni LI

更新日期：2006-06-01 00:00:00

abstract：OBJECTIVE:To estimate the clinical and economic benefits of memantine treatment initiated in moderate Alzheimer's disease (AD) in China, compared with initiation in severe AD only. METHODS:A Markov model with a 5-year time horizon simulated moderate patients' progression through health states. Two groups were compared...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hu S,Yu X,Chen S,Clay E,Toumi M,Milea D

更新日期：2015-01-01 00:00:00

abstract：:Given the lack of evidence from randomized controlled trials and large prospective studies, controversy exists regarding the optimal treatment strategy for early stage prostate cancer. The impact of various treatments on health-related quality of life has become an increasingly important but controversial issue. The l...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： D'haese S,Bottomley A

更新日期：2004-06-01 00:00:00

abstract：:This paper acknowledges the difficulties of providing access to innovative drugs in some jurisdictions under the patent system and it contributes to the current debate on mechanisms aimed at facilitating such access. We employ a highly stylized static model of two markets (North and South) to analyse the conditions un...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Antoñanzas F,Rodríguez-Ibeas R,Juárez-Castelló CA

更新日期：2014-10-01 00:00:00

abstract：:It is a continual challenge trying to improve the quality of prescribing while concurrently trying to address increasing pharmaceutical development, utilization and expenditure. National and regional reforms and initiatives in Sweden have moderated growth in ambulatory drug expenditure to 2.7% per annum in recent year...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Godman B,Wettermark B,Hoffmann M,Andersson K,Haycox A,Gustafsson LL

更新日期：2009-02-01 00:00:00

abstract：:Most national guidelines for pharmacoeconomic research prescribe discounting, mostly of money and health against the same rate. There is much debate on whether this is adequate. Two theoretical arguments, the consistency argument of Weinstein and Stason, and the paralyzing paradox of Keeler and Cretin, are mostly resp...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Klock RM,Brouwer WB,Annemans LJ,Bos JM,Postma MJ

更新日期：2005-02-01 00:00:00

abstract：:This article reviews the literature reporting empirically determined symptom clusters in patients with metastatic cancer. A literature search was conducted on symptom clusters within heterogeneous metastatic cancer patient populations using MEDLINE, EMBASE, and CINAHL. Studies examining predetermined symptom clusters ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Thavarajah N,Chen E,Zeng L,Bedard G,Di Giovanni J,Lemke M,Lauzon N,Zhou M,Chu D,Chow E

更新日期：2012-10-01 00:00:00

abstract：:The assessment of longitudinal change in subjective patient-reported outcomes such as health-related quality of life (HRQoL) is a key component of many clinical and research evaluations. A major goal of measuring patient-reported HRQoL is to determine to what extent changes in HRQoL reports over time represent true ch...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Hamidou Z,Dabakuyo TS,Bonnetain F

更新日期：2011-10-01 00:00:00

abstract：:In response to concerns about the cost burden of medical care in general and rising pharmaceutical costs in particular, a number of recent studies have examined trends in pharmaceutical expenditures. These studies have reached apparently disparate conclusions about factors responsible for rising pharmaceutical costs a...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Crown WH,Ling D,Berndt E

更新日期：2002-10-01 00:00:00

abstract：:Cancer patient satisfaction assessment is increasingly considered, owing to the need to assess evolving patterns of care organization and delivery or to test new cancer treatments and interventions. This article reviews cancer patient satisfaction questionnaires using key methodological criteria. In total, 17 patient ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Brédart A,Sultan S,Regnault A

更新日期：2010-04-01 00:00:00

abstract：:Prostate cancer is the most common non-skin cancer in American men, and prostate-specific antigen (PSA) testing is its common screening procedure. In May 2012, the US Preventive Services Task Force recommended against PSA-based screening. These recommendations contradict the current recommendations of other organizati...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Garg V,Gu NY,Borrego ME,Raisch DW

更新日期：2013-06-01 00:00:00

abstract：:In health and disability arenas, it is increasingly being recognized that removing or modifying environmental factors can have a greater influence over outcomes than many individually focused interventions. In 2001, the World Health Organization endorsed a major revision of its framework for assessing and classifying ...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Kuipers P,Foster MM,Bellamy N

更新日期：2003-04-01 00:00:00

abstract：:The 15th International Symposium for Health Information Management Research (ISHIMR) was organized jointly by University Hospital Zurich (Switzerland), the University of St Gallen (St Gallen, Switzerland) and the University of Sheffield (Sheffield, UK). Participants included researchers, healthcare professionals, heal...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Bath PA,Sen BA,Raptis DA,Mettler T

更新日期：2012-02-01 00:00:00

abstract：:Adalimumab is a monoclonal antibody that inhibits TNF, an osteogenic cytokine involved in the pathogenesis of chronic, disabling inflammatory diseases. Adalimumab is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. It alleviates the symptoms of these diseases, preven...

journal_title：Expert review of pharmacoeconomics & outcomes research

authors： Gladman DD,Brown RE

更新日期：2008-04-01 00:00:00